Exosomes are small membrane-enclosed vesicles actively secreted by most cells into biological fluids including serum, plasma, urine, breast milk, and saliva [1]. Studies have found that the analysis of exosome-associated nucleic acids, proteins and/or lipids can indicate the presence of a range of cancers, including pancreatic cancer, colorectal cancer [2], breast cancer [3], and non-small cell lung cancer [4].

That is why exosomes represent an exciting new avenue of cancer diagnosis. As a group of promising biomarkers, the analysis of biomarkers associated with exosomes in blood may offer a minimally invasive route for cancer diagnosis and prognosis.[5]

Extraction and isolation

Despite the explosion in exosome research and their potential in disease (especially cancer) diagnostics, exosome-associated biomarkers have not yet been translated to meet the rapid developments in molecular medicine for commercial liquid biopsy applications. This is primarily due to the limitations of current exosome capture and isolation methods, which are time consuming, operator dependent and not scalable.

INOVIQ’s EXO-NET® for exosome capture (Research Use Only)

INOVIQ’s EXO-NET® product allows for fast, accurate and efficient capture and isolation of exosomes from any liquid biopsy sample. The technology is highly scalable and is compatible with existing automated testing systems making it ideal for high volume clinical laboratory applications.

For more information, including pricing and ordering, visit www.exo-net.com

EXO-NET® beads demonstrate superior exosome capture ability in comparison to a commercial competitor, as evidenced by the concentration of known CD63 and CD9 exosome specific biomarkers. In addition to demonstrating outperformance compared to commercial products, EXO-NET for RUO demonstrates outperformance against ultra-centrifugation (the recognised research gold-standard method), in a fraction of the time (15 minutes versus 6-12 hours).

For more information, and for pricing and ordering, go to www.exo-net.com

Visit our EXO-NET® Product Website Here: WWW.EXO-NET.COM


[1] Mathai RA, Vidya RV, Reddy BS, et al. Potential utility of liquid biopsy as a diagnostic and prognostic tool forthe assessment of solid tumors: Implications in the precision oncology. J Clin Med 2019; 8(3):373

[2] Qi Z-H, Xu H-X, Shi-Rong Zhang S-R, Xu J-Z, et al. The significance of liquid biopsy in pancreatic cancer. J Cancer 2018; 9(18): 3417-3426. doi: 10.7150/jca.24591

[3] Chen Y, Xie Y, Xu L, et al. Protein content and functional characteristics of serum-purified exosomes from patients with colorectal cancer revealed by quantitative proteomics. Int J Cancer 2017; 140: 900–913

[4] Meng Y, Sun J, Wang X, et al. Exosomes: A promising avenue for the diagnosis of breast cancer. Technol Cancer Res Treat 2019; 18:1-14.

[5] Masaoutis C, Mihailidou C, Tsourouflis G, Theocharis S. Exosomes in lung cancer diagnosis and treatment. From the translating research into future clinical practice. Biochimie 2018; 151: 27-36. doi:10.1016/j.biochi.2018.05.014